Skip to main content
OpenTrials
Completed

NCT Number: NCT05383378

A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis

This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo. Initially, 2 sentinel subjects will be treated (randomized to placebo or si-544) in each cohort.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Neurodermatitis Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

selectION Clinical Trial Site, Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

SAD and MAD part

  • Subject has the capacity for consenting, was informed about the nature, the scope, and the relevance of the clinical study, voluntarily agrees in participation and in the study provisions, and duly signed the informed consent form approved by the ethics committee before any study-related procedure.
  • Men and women aged ≥18 to 75 years
  • Willing and able to adhere to the protocol requirements
  • {deleted}
  • Women of childbearing potential must:
  • have a negative pregnancy test (blood) at Screening.
  • agree to use, and be able to comply with, highly effective measures of contraceptive control (failure rate less than 1% per year when used consistently and correctly) without interruption, from Screening through 30 days after the last IMP treatment.

Reliable methods for this study are:

i. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) ii. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) iii. intrauterine device iv. intrauterine hormone-releasing system v. bilateral tubal occlusion vi. vasectomized sexual partner (provided that the partner is the sole sexual partner of the woman of childbearing potential and has received medical assessment of the surgical success) vii. sexual abstinence (only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment) Abstinence is only accepted as true abstinence: when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods and withdrawal] is not an acceptable method of contraception).

c. agree to abstain from breast feeding during the study participation and for 90 days after the last IMP treatment.

Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile women (tubal ligation, hysterectomy, or bilateral oophorectomy) may be enrolled.

  • Men must practice true abstinence or agree to use a condom during sexual contact with a pregnant woman or a woman of childbearing potential for at least 90 days after the last IMP treatment, even after undergoing a successful vasectomy.

SAD part only

  • Clinical diagnosis of mild to severe AD

MAD part only

  • Clinical diagnosis of mild to severe AD with a SCORAD ≥15

Exclusion criteria

SAD and MAD part

  • Change (ie, starting anew, change in frequency, or change in drug substance) in standard systemic and topical therapy, or in immunosuppressive drug therapy within 4 weeks before Screening (for biologics such as dupilumab, the therapy may not be changed within 12 weeks before Screening), as judged by the investigator
  • Known history of hypersensitivity to constituents or excipients in the pharmaceutical formulation of the IMP
  • Uncontrolled hypertension or uncontrolled diabetes
  • History of seizures
  • Presence or history of paresthesia or neuropathy
  • Clinically significant ECG abnormalities, as judged by the investigator
  • Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, renal, or other major systemic disease, as judged by the investigator
  • Presence of acute infection within 7 days before Screening, as judged by the investigator
  • Known or active infection with Mycobacterium tuberculosis
  • Known or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
  • Vaccination within 2 weeks before Screening and/or planned vaccination during the SAD part or the treatment period of the MAD part
  • Pregnancy
  • Any finding or medical condition prohibiting the inclusion in the study, as judged by the investigator
  • Current or previous (within 4 weeks before Screening) participation in another clinical study with an investigational medicinal product or medical device
  • Known or suspected abuse of alcohol, drugs, or medicinal products
  • Employee of the sponsor, or employee, or relative of the investigator
  • Use of prohibited medication
  • Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
  • Legal incapacity or limited legal capacity

MAD part

  • Previous participation in the SAD part of this study with IMP dosing within 3 months before the planned first dosing of the MAD part.

Treatment and study plan

si-544

Drug

Subcutaneous injection in the abdomen

Placebo

Drug

Subcutaneous injection in the abdomen

Primary outcomes

  1. Adverse events (AEs)

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    AEs will be summarized and tabulated according to the primary system organ class and preferred term. Separate analyses will be conducted using severity, seriousness, and relationship to the IMP.

  2. Adverse events (AEs)

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    AEs will be summarized and tabulated according to the primary system organ class and preferred term. Separate analyses will be conducted using severity, seriousness, and relationship to the IMP.

  3. Change from Baseline in hematology parameter plateletes to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter platelets the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  4. Change from Baseline in hematology parameter plateletes to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter platelets the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  5. Change from Baseline in hematology parameter erythrocytes to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter erythrocytes the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  6. Change from Baseline in hematology parameter erythrocytes to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter erythrocytes the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  7. Change from Baseline in hematology parameter leukocytes to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter leukocytes the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  8. Change from Baseline in hematology parameter leukocytes to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter leukocytes the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  9. Change from Baseline in hematology parameter differential leukocyte count to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter differential leukocyte count the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  10. Change from Baseline in hematology parameter differential leukocyte count to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter differential leukocyte count the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  11. Change from Baseline in hematology parameter hemoglobin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter hemoglobin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  12. Change from Baseline in hematology parameter hemoglobin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter hemoglobin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  13. Change from Baseline in hematology parameter hematocrit to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter hematocrit the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  14. Change from Baseline in hematology parameter hematocrit to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter hematocrit the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  15. Change from Baseline in hematology parameter mean corpuscular volume to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter mean corpuscular volume the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  16. Change from Baseline in hematology parameter mean corpuscular volume to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter mean corpuscular volume the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  17. Change from Baseline in hematology parameter mean corpuscular hemoglobin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter mean corpuscular hemoglobin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  18. Change from Baseline in hematology parameter mean corpuscular hemoglobin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter mean corpuscular hemoglobin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection

  19. Change from Baseline in hematology parameter mean corpuscular hemoglobin concentration to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of hematology parameter mean corpuscular hemoglobin concentration the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  20. Change from Baseline in hematology parameter mean corpuscular hemoglobin concentration to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of hematology parameter mean corpuscular hemoglobin concentration the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  21. Change from Baseline in alanine aminotransferase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of alanine aminotransferase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  22. Change from Baseline in alanine aminotransferase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of alanine aminotransferase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  23. Change from Baseline in aspartate aminotransferase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of aspartate aminotransferase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  24. Change from Baseline in aspartate aminotransferase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of aspartate aminotransferase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  25. Change from Baseline in gamma-glutamyl transferase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of gamma-glutamyl transferase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  26. Change from Baseline in gamma-glutamyl transferase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of gamma-glutamyl transferase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  27. Change from Baseline in alkaline phosphatase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of alkaline phosphatase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  28. Change from Baseline in alkaline phosphatase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of alkaline phosphatase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  29. Change from Baseline in total bilirubin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of total bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  30. Change from Baseline in total bilirubin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of total bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  31. Change from Baseline in unconjugated (indirect) bilirubin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of unconjugated (indirect) bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  32. Change from Baseline in unconjugated (indirect) bilirubin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of unconjugated (indirect) bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  33. Change from Baseline in conjugated (direct) bilirubin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of conjugated (direct) bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  34. Change from Baseline in conjugated (direct) bilirubin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of conjugated (direct) bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  35. Change from Baseline in blood urea nitrogen to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood urea nitrogen the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  36. Change from Baseline in blood urea nitrogen to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood urea nitrogen the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  37. Change from Baseline in creatinine to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of creatinine the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  38. Change from Baseline in creatinine to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of creatinine the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  39. Change from Baseline in uric acid to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of uric acid the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  40. Change from Baseline in uric acid to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of uric acid the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  41. Change from Baseline in estimated glomerular filtration rate to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of estimated glomerular filtration rate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  42. Change from Baseline in estimated glomerular filtration rate to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of estimated glomerular filtration rate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  43. Change from Baseline in blood biochemistry parameter sodium to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter sodium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  44. Change from Baseline in blood biochemistry parameter sodium to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter sodium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  45. Change from Baseline in blood biochemistry parameter potassium to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter potassium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  46. Change from Baseline in blood biochemistry parameter potassium to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter potassium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  47. Change from Baseline in blood biochemistry parameter magnesium to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter magnesium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  48. Change from Baseline in blood biochemistry parameter magnesium to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter magnesium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  49. Change from Baseline in blood biochemistry parameter chloride to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter chloride the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  50. Change from Baseline in blood biochemistry parameter chloride to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter chloride the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  51. Change from Baseline in blood biochemistry parameter inorganic phosphate to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter inorganic phosphate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  52. Change from Baseline in blood biochemistry parameter inorganic phosphate to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter inorganic phosphate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  53. Change from Baseline in blood biochemistry parameter calcium to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter calcium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  54. Change from Baseline in blood biochemistry parameter calcium to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter calcium the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  55. Change from Baseline in blood biochemistry parameter creatine phosphokinase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter creatine phosphokinase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  56. Change from Baseline in blood biochemistry parameter creatine phosphokinase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter creatine phosphokinase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  57. Change from Baseline in blood biochemistry parameter amylase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter amylase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  58. Change from Baseline in blood biochemistry parameter amylase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter amylase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  59. Change from Baseline in blood biochemistry parameter lipase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter lipase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  60. Change from Baseline in blood biochemistry parameter lipase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter lipase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  61. Change from Baseline in blood biochemistry parameter total protein to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter total protein the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  62. Change from Baseline in blood biochemistry parameter total protein to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter total protein the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  63. Change from Baseline in blood biochemistry parameter albumin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter albumin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  64. Change from Baseline in blood biochemistry parameter albumin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter albumin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  65. Change from Baseline in blood biochemistry parameter glucose (non-fasting) to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter glucose (non-fasting) the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  66. Change from Baseline in blood biochemistry parameter glucose (non-fasting) to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter glucose (non-fasting) the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  67. Change from Baseline in blood biochemistry hemoglobin A1c to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter hemoglobin A1c the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  68. Change from Baseline in blood biochemistry hemoglobin A1c to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter hemoglobin A1c the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  69. Change from Baseline in blood biochemistry triglycerides to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter triglycerides the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  70. Change from Baseline in blood biochemistry triglycerides to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter triglycerides the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  71. Change from Baseline in blood biochemistry cholesterol to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter cholesterol the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  72. Change from Baseline in blood biochemistry cholesterol to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter cholesterol the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  73. Change from Baseline in blood biochemistry ferritin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter ferritin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  74. Change from Baseline in blood biochemistry ferritin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter ferritin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  75. Change from Baseline in blood biochemistry D-dimer to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter D-dimer the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  76. Change from Baseline in blood biochemistry D-dimer to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter D-dimer the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  77. Change from Baseline in blood biochemistry lactate dehydrogenase to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter lactate dehydrogenase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  78. Change from Baseline in blood biochemistry lactate dehydrogenase to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter lactate dehydrogenase the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  79. Change from Baseline in blood biochemistry C-reative protein to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood biochemistry parameter C-reactive protein the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  80. Change from Baseline in blood biochemistry C-reative protein to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood biochemistry parameter C-reactive protein the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  81. Change from Baseline in blood coagulation partial thromboplastin time to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood coagulation parameter partial thromboplastin time the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  82. Change from Baseline in blood coagulation partial thromboplastin time to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood coagulation parameter partial thromboplastin time the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  83. Change from Baseline in blood coagulation parameter prothrombin time to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood coagulation parameter prothrombin time the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  84. Change from Baseline in blood coagulation parameter prothrombin time to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood coagulation parameter prothrombin time the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  85. Change from Baseline in blood coagulation parameter international normalized ratio (INR) all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood coagulation parameter international normalized ratio (INR) the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  86. Change from Baseline in blood coagulation parameter international normalized ratio (INR) all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood coagulation parameter international normalized ratio (INR) the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  87. Change from Baseline in urinalysis parameter pH to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter pH the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  88. Change from Baseline in urinalysis parameter pH to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter pH the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  89. Change from Baseline in urinalysis parameter leukocytes to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter leukocytes the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  90. Change from Baseline in urinalysis parameter leukocytes to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter leukocytes the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  91. Change from Baseline in urinalysis parameter nitrites to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter nitrites the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  92. Change from Baseline in urinalysis parameter nitrites to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter nitrites the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  93. Change from Baseline in urinalysis parameter blood to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter blood the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  94. Change from Baseline in urinalysis parameter blood to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter blood the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  95. Change from Baseline in urinalysis parameter protein to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter protein the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  96. Change from Baseline in urinalysis parameter protein to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter protein the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  97. Change from Baseline in urinalysis parameter glucose to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter glucose the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  98. Change from Baseline in urinalysis parameter glucose to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter glucose the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  99. Change from Baseline in urinalysis parameter ketones to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter ketones the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  100. Change from Baseline in urinalysis parameter ketones to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter ketones the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  101. Change from Baseline in urinalysis parameter urobilinogen to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter urobilinogen the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  102. Change from Baseline in urinalysis parameter urobilinogen to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter urobilinogen the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  103. Change from Baseline in urinalysis parameter bilirubin to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of urinalysis parameter bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  104. Change from Baseline in urinalysis parameter bilirubin to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of urinalysis parameter bilirubin the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  105. Change from Baseline in 12-lead ECG parameter PR-interval to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of 12-lead ECG parameter PR-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  106. Change from Baseline in 12-lead ECG parameter PR-interval to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of 12-lead ECG parameter PR-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  107. Change from Baseline in 12-lead ECG parameter QRS-interval to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of 12-lead ECG parameter QRS-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  108. Change from Baseline in 12-lead ECG parameter QRS-interval to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of 12-lead ECG parameter QRS-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  109. Change from Baseline in 12-lead ECG parameter QT-interval to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of 12-lead ECG parameter QT-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  110. Change from Baseline in 12-lead ECG parameter QT-interval to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of 12-lead ECG parameter QT-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  111. Change from Baseline in 12-lead ECG parameter QTc[F]-interval to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of 12-lead ECG parameter QTc[F]-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  112. Change from Baseline in 12-lead ECG parameter QTc[F]-interval to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of 12-lead ECG parameter QTc[F]-interval the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  113. Change from Baseline in peripheral oxygen saturation to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of peripheral oxygen saturation the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  114. Change from Baseline in peripheral oxygen saturation to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of peripheral oxygen saturation the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  115. Change from Baseline in blood pressure to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of blood pressure the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  116. Change from Baseline in blood pressure to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of blood pressure the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  117. Change from Baseline in heart rate to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of heart rate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  118. Change from Baseline in heart rate to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of heart rate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  119. Change from Baseline in respiration rate to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of respiration rate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  120. Change from Baseline in respiration rate to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of respiration rate the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  121. Change from Baseline in body temperature to all assessments during the study

    Time frame: SAD part: Between Day 1 (IMP injection) and Day 8 (last visit)

    For the analyses of body temperature the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

  122. Change from Baseline in body temperature to all assessments during the study

    Time frame: MAD part: Between Day 1 (first IMP injection) and Day 106 (last visit)

    For the analyses of body temperature the absolute values, and changes from Baseline will be summarized for all assessed time points. Baseline is defined as the last assessment before IMP injection.

Secondary outcomes

  1. SAD part: Plasma concentration of free si-544 in blood plasma at Day 1

    Time frame: Day 1

    Blood collections up to 15 minutes before, and immediately, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours after IMP injection. The sampling window will be ±1 minute for ≤1 hour, ±5 minutes for 2 hours, ±15 minutes for 4 hours, and ±30 minutes for 8 hours post injection.

    Plasma concentration of free si-544 in blood plasma will be analyzed by descriptive statistics by treatment group.

  2. MAD part: Plasma concentration of free si-544 in blood plasma at Days 1 and 25

    Time frame: Day 1 and Day 25

    Blood collections up to 15 minutes before, and immediately, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 8 hours after IMP injection. The sampling window will be ±1 minute for ≤1 hour, ±5 minutes for 2 hours, ±15 minutes for 4 hours, and ±30 minutes for 8 hours post injection.

    Plasma concentration of free si-544 in blood plasma will be analyzed by descriptive statistics by treatment group and visit.

  3. MAD part: Change from Baseline in number of T cells in peripheral blood at Day 29, and Weeks 8, 12, and 16

    Time frame: Day 1, Day 29, Week 8, Week 12, and Week 16 (last visit)

    Blood sampling window on Day 1: up to 15 minutes before IMP injection.

  4. MAD part: Change from Baseline in immunophenotyping of T-cell subsets at Day 29, and Weeks 8, 12, and 16

    Time frame: Day 1, Day 29, Week 8, Week 12, and Week 16 (last visit)

    Blood sampling window on Day 1: up to 15 minutes before IMP injection.

  5. MAD part: Change from Baseline in serum cytokine levels at Day 29, and Weeks 8, 12, and 16

    Time frame: Day 1, Day 29, Week 8, Week 12, and Week 16 (last visit)

    Blood sampling window on Day 1: up to 15 minutes before IMP injection.

  6. MAD part: Optional: Change from Baseline of expression levels of Kv1.3 vs KCa3.1 of effector memory T cells at Day 29, and Weeks 8, 12, and 16

    Time frame: Day 1, Day 29, Week 8, Week 12, and Week 16 (last visit)

    Blood sampling window on Day 1: up to 15 minutes before IMP injection.

  7. Change from Baseline in anti-drug antibodies against si-544 in serum at Day 29

    Time frame: Day 1 and Day 29

    Blood sampling window on Day 1: up to 15 minutes before IMP injection.

  8. Change from Baseline in inflamed areas using the body surface area index at Days 15 and 29, and Weeks 8, 12, and 16

    Time frame: Day 1, Day 15, Day 29, Week 8, Week 12, and Week 16 (last visit)

    The body surface index will be used to assess the inflamed skin areas as percentage of the total body surface area (BSA). Percentage of BSA affected by AD with each body part accounted for by: head and neck: 9%, upper limbs: 9% each, lower limbs: 18% each, anterior trunk: 18%, back: 18%, and genitals: 1%. The score for each affected area is added up with the total possible (ie, all areas affected) score for being 100 (ie, 100% of BSA).

  9. Change from Baseline in atopic dermatitis (AD) severity by SCOring AD (SCORAD) at Days 15 and 29, and Weeks 8, 12, and 16

    Time frame: Day 1, Day 15, Day 29, Week 8, Week 12, and Week 16 (last visit)

    The AD severity assessment will be done by SCORing Atopic Dermatitis (SCORAD). SCORAD is a composite score of 3 components: (A) the BSA involved in AD, (B) the severity of 6 clinical signs, and (C) a subject-reported component assessing pruritus and sleep loss. The total score is calculated with a maximal total score of 103. A score <25 indicates mild, score 25-60 moderate, and score 61-103 severe AD.

Sponsors and collaborators

Lead sponsor

selectION Therapeutics GmbH

Industry

Collaborators

  • FGK Clinical Research GmbH

Registry information

Official study title

A Multi-center, Phase 1b, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 20, 2022
Registry last updated
Nov 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.